From lighting landmarks in blue to showcasing patient stories, supporters are finding ways to mark Pulmonary Fibrosis Awareness Month, set aside each September to call attention to the lung condition and raise funds to fight it. The monthlong campaign is spearheaded each year by the Pulmonary Fibrosis Foundation…
Across the Globe, Supporters Go Blue for PF Awareness Month
A new 3D model of lung tissue allowed the scientists who developed it to identify aspects of pulmonary fibrosis (PF) not evident in the 2D models often used in research. This new model, developed by a research team at the University of Michigan, revealed potentially important aspects of fibrosis and…
Using Cymerus mesenchymal stem cells (MSCs) to treat idiopathic pulmonary fibrosis (IPF) resulted in dramatic reductions in IPF symptoms and significant improvements in lung functionality in an animal model of the disease, Cynata Therapeutics, the company developing this stem cell therapy, reported. These…
In recognition of September being Pulmonary Fibrosis Awareness Month, the Pulmonary Fibrosis Foundation (PFF) is working to raise awareness about the realities of this disease and how it affects people’s lives. The PFF is also conducting a social media campaign, “30 Facts in 30 Days,” to educate the public…
The University of California, San Francisco (UCSF), where my mom, Holly, received her double-lung transplant, has gone to great lengths to provide information at every turn on the transplant journey. The infamous blue binder contains everything you need to know about post-transplant life. UCSF’s approach to transplant…
Procalcitonin, a precursor of the calcitonin hormone, may be used as a potential biomarker of lung cancer developing in people with idiopathic pulmonary fibrosis (IPF), a recent study suggests. Compared with patients with IPF alone, procalcitonin was significantly higher in IPF patients who also had lung…
It’s common for young adults in their early 30s to plan for their future. For some, this might include planning for a beautiful wedding or having a family. For others, it might mean traveling the world, buying a dream home, or landing the ideal job. My ideal future would include…
An inhaled formulation of nintedanib — the active ingredient in Ofev — demonstrated enhanced antifibrotic effects after short-duration doses compared to oral formulations given at a higher dose in a rat model with induced idiopathic pulmonary…
Ofev (nintedanib) is safe and effective for adults with idiopathic pulmonary fibrosis (IPF) with poorer lung function, a small real-world analysis has found. Age and lung function predicted the therapy’s efficacy in this group of patients. …
Research investigating the role of immune cells in triggering lung and heart rejection following transplant will be supported by $10 million in grants from the National Institutes of Health (NIH). The grants, awarded to scientists at Washington University School of Medicine in St. Louis, will support research that aims…
Your PF Community
Recent Posts
- Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data December 17, 2025
- The greatest gift I’ve received wasn’t under the Christmas tree December 16, 2025
- Reversing caregiver roles taught me about emotional presence December 16, 2025
- Our response to a PF diagnosis was achieving a ‘life beyond limits’ December 11, 2025
- New IPF treatment moves ahead after encouraging study results December 10, 2025
